Liquid Biopsy-Based Androgen Receptor Alterations Associated With Advanced Prostate Cancer Outcomes

May 02, 2019

|

NEW YORK (GenomeWeb) – A team from Sweden, Belgium, and the UK has found evidence that an increasing number of androgen receptor splicing shifts and alterations in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) may be promising blood markers for treatment resistance and survival outcomes in advanced prostate cancer patients with TP53 mutation-free tumors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Scott Gottlieb Goes Back to His Old Job

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Where No CRISPR Has Gone Before

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Two Leave Emory

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

This Week in Science

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.

Featured White Papers

Cell Engineering 101

CRISPR 101

Gene Knockouts: How CRISPR Is Used to Inactivate Genes

Compatibility of liquid biopsy assays on multiple sequencing platforms

Jun

04

Featured Webinar

A CRISPR Study to Decipher the Role of Genetic Risk Variants in Glaucoma

This webinar will discuss a study that used CRISPR/Cas9 to engineer mice harboring risk variants associated with glaucoma in order to assess their functional relevance.

Jun

06

Featured Webinar

Accelerating Crop Research with High-Quality Affordable Genome Assemblies

This webinar will discuss the impact of affordable de novo genome assemblies on crop research.

Jun

11

Featured Webinar

The Promise of Liquid Biopsy in Lung Cancer Monitoring

This webinar will overview the potential for liquid biopsy approaches to monitor therapy resistance in lung cancer.

Jun

13

Featured Webinar

Lowering RNA-seq Costs via Enzymatic rRNA Depletion with Custom, Species-specific Probes

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type.

Menu